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ABSTRACT: This study investigated whether and how gypenosides from jiaogulan tea at 100 and 300 mg/kg/day levels could
reduce the development of overweight and insulin resistance in C57 BL/6J mice fed a high-fat diet in 12 weeks. The 300 mg/kg/
day gypenosides supplement significantly reduced final body weight, plasma total cholesterol, and homeostasis model
assessment-estimated insulin resistance (HOMA-IR) index by 19.9%, 40%, and 36%, respectively, compared with the high-fat
diet control group. Gypenosides also increased brown adipocyte tissue activity and white adipose tissue browning. The
expression of genes involved in mitochondrial activity and fatty acid β-oxidation were also increased in both brown and white
adipocyte tissues. In addition, gypenosides at 100 and 300 mg/kg/day levels decreased the ratio of Firmicutes to Bacteroidetes by
20% and 58.6%, respectively, and increased Akkermansia muciniphila abundance in the gut microbiota.
KEYWORDS: gypenosides, obesity, insulin resistance, white adipocyte tissue, brown adipocyte tissue, microbiota
■ INTRODUCTION
White adipose tissue (WAT) plays an important role in
regulating the whole body homeostasis and stores energy in the
triglycerides (TGs) form, whereas brown adipose tissue (BAT)
utilizes lipids for heat production. The BAT function is
mediated by the tissue-specific uncoupling protein 1 (UCP-1)
located in the mitochondria and dissociates cellular respiration
from ATP utilization to convert the stored energy to heat.1,2
BAT activity in humans is inversely correlated with adiposity,
blood glucose concentrations, and insulin resistance.2 Manip-
ulating WAT to acquire BAT-like characteristics is considered a
possible approach to reduce the risk of overweight and obesity.3
Despite advances in knowledge regarding the developmental
lineage and transcriptional regulators of brown and beige
adipocytes, current knowledge on whether and how food
factors and other environmental modifiers may alter BAT
thermogenesis is limited.4,5
Jiaogulan, Gynostemma pentaphyllum Makino (GP), is a
perennial liana vine widely spread in Asian countries, and its
leaves have been used in food and tea.6 Gypenosides are
considered the major bioactive constituents in GP and have
been shown to reduce the potential development of obesity,7
cardiovascular diseases,8 diabetes,9 inflammation,6,10 and
cancer.11,12 A previous study showed that gypenosides could
curb obesity in an ob/ob mouse model through activating AMP-
activated protein kinase.13 Park et al. confirmed the potential
antiobesity and safety of gypenosides at 450 mg/kg/day level
through a 12-week, 80 Korean participant, randomized, double-
blind, placebo-controlled clinical trial.7 Interestingly, gypeno-
sides were able to inhibit adipogenesis through modulating the
Wnt/β-catenin pathway and cell cycle in mitotic clonal
expansion in one of our recent studies.14 However, these
previous studies did not investigate the possible molecular
mechanisms behind the antiobesity capacity of gypenosides or
their effects on adipocytes such as stimulating BAT activity and
browning of white adipose tissue.
In addition, gut microbiota may play a role in the
development of the obese and diabetic phenotypes.15 An
increase in the major phyla Firmicutes/Bacteroidetes ratio and
changes in several bacterial species have been shown to increase
the risk of obesity in both genetic and dietary model mice.16
Alterations in the gut microbial community may impact the
host capacity to extract energy from a given diet, thereby
triggering the development of obesity and related diabetes.17,18
Another study reported that transplanting the “cold microbiota”
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to germ-free mice was able to increase insulin sensitivity of the
host and its tolerance to cold partially through inducing the
white fat browning and resulting in an increased fat loss and
energy expenditure.1 The cold microbiota referred to the
microbiota in C57 BL/6 mice exposed to 6 °C for 30 days
under a SPF condition. The results indicate a possible link
between the gut microbiota and the energy homeostasis of the
host.1 Therefore, it is interesting whether gypenosides may alter
glucose metabolism and body weight gain through modulating
the gut microbiota.
In this study, the effect of gypenosides on the risk of obesity
and insulin resistance and their possible roles in β-oxidation
and mitochondrial function, BAT activity, and WAT browning
were investigated in a high-fat diet-induced obese mouse
model. Their effects on gut microbiota composition were also
examined as a possible mechanism behind their capacity in
reducing the development of overweight and related diabetes.
■ MATERIALS AND METHODS
Reagents and Materials. The leaves of tetraploid jiaogulan (G.
pentaphyllum (Thunb.) Makino) were collected and identified by
Baicaotang Biotechnology Co. Ltd., Pingli, Shanxi Province of China,
in 2013. Botanicals were kept at 4 °C until extraction. A voucher
specimen (no. 2013003) has been deposited in our laboratory, at the
School of Agriculture and Biology, Shanghai Jiao Tong University,
Shanghai, China. Gypenosides were prepared according to a laboratory
procedure, which contained nine different dammarane-type saponins
with a purity > 95%.
Gypenosides contained 10.84% (GP-1), 7.57% (GP-2), 24.10% (GP
3 + GP 4), 26.12% (GP 5 + GP 6 + GP 7), 24.76% (GP-8), and 5.60%
(GP-9).19
Animal and Diet. Thirty-two male C57 BL/6J mice (5 weeks old,
Charles River Laboratories, Beijing, China) were used in this study. All
animal experiment procedures were approved with permission number
A2015024 by the Medical Ethics Committee of Shanghai Jiao Tong
University and in accordance with the National Institutes of Health
regulations for the care and use of animals in research. All animals
were housed individually in polycarbonate cages in an animal care
facility at 22−24 °C and 40−50% relative humidity, lights were on
during 9:00−21:00, and mice were fed the AIN-76 semipurified diet
for a 1-week acclimation period. They were subsequently divided
randomly into four groups and fed a low-fat diet (LFD, n = 8,
D12450B, Research Diets Inc., NJ, USA), high-fat diet (HFD, n = 8,
D12451, Research Diets Inc., NJ, USA), or HFD with 100 mg/kg
gypenosides (HFD+L, n = 8) and 300 mg/kg gypenosides (HFD+H, n
= 8) for 12 weeks. All experimental diets were changed every 3 days
and stored at 4 °C. The body weights and food intakes were
monitored every week. At the end of the experimental period, all mice
were anesthetized after a 12 h fast. Blood was taken from the inferior
vena cava to determine the glucose, plasma lipid, and insulin
concentrations. Feces were collected for three consecutive days prior
to animal sacrifice and stored at −80 °C for macrobiotic analysis. All
organ tissues were harvested, weighed, immediately frozen in
RNALater (Invitrogen) or liquid nitrogen, and stored at −80 °C for
biochemical and molecular analyses.
Oral Glucose Tolerance Test (OGTT) and Intraperitoneal
Insulin Tolerance Test (IPITT). After 12 weeks of different
concentrations of gypenosides administration, the mice were fasted 6
h and orally given glucose at a 1.5 g/kg body weight level for oral
glucose tolerance test (OGTT) and fasted for 4 h and intraperitoneally
injected insulin at a concentration of 0.75 unit/kg body weight for
intraperitoneal insulin tolerance test (IPITT). The blood glucose
concentrations were determined at 0, 30, 60, 90, and 120 min after
feeding or injection with a portable glucose meter (One-touch
UltraEasy, Johnson Medical, Beijing, China). A glucose concen-
tration−time plot was prepared to show the changes in glucose levels
with time and to calculate the integrated areas under each curve
(AUC) for OGTT and IPITT.20
Quantification of Plasma Lipids, Glucose, and Homeostatic
Model Assessment of Insulin Resistance (HOMA-IR). Plasma
samples were obtained by centrifugation at 3500 rpm and 4 °C for 10
min. Plasma total cholesterol (TC) and triglycerides (TG) were
enzymatically determined using commercial kits (LabAssay Trigly-
ceride/Cholesterol Kit, Wako, Osaka, Japan), and fasting glucose
concentrations were determined using the portable glucose meter. The
plasma insulin levels were measured by ELISA assays according to the
manufacturer’s instructions (EZRMI-13K, Millipore, Germany).
HOMA-IR index was calculated as [fasting insulin concentration
(mU/L) × fasting glucose concentration (mmol/L)]/22.5.20
Morphological and Immunohistochemistry. Perirenal adipose
tissues were fixed in 4% paraformaldehyde and were sectioned after
being paraffin embedded. Multiple sections were stained with
hematoxylin and eosin for general morphological observations.
Immunohistochemistry staining was performed according to the
standard protocol using the UCP1 antibody with 1:100 dilution
(Abcam, Oxford, UK).
Real-Time PCR. To measure mRNA expression changes, different
adipose tissues with different treatments preserved in RNALater were
cut into 0.1−0.2 g pieces and homogenized using a Precellys 24
(Bertin Technologies, Villeurbanne, France). RNeasy Mini Kit
(Qiagen, Valencia, CA) was used for total RNA isolation. A 0.2 μg
amount of first-strand cDNA synthesis was performed using an iScript
reverse transcriptase kit (Bio-Rad) and subsequently used for
quantitative real-time PCR analysis. qRT-RCR was conducted using
SYBR Green mix and ABI 7900 HT (Applied Biosystems, Carlsbad,
CA). PCR amplification was performed as follows: 50 °C for 2 min, 95
°C for 10 min, and 46 cycles of amplification at 95 °C for 15 s and 60
°C for 1 min. Statistical analysis of quantitative real-time PCR was
performed using the 2−ΔΔCt method as previously reported,19 which
calculates the relative changes in gene expression of the target,
normalized to the endogenous reference β-actin and relative to a
control calibrator. Forward and reverse primer sequences are shown in
Table S1 in the Supporting Information.
Western Blotting. Homogenized tissue samples were lysed in 200
μL of ice-cold radioimmunoprecipitation assay (RIPA) buffer
containing a protease inhibitor cocktail (Sigma, St. Louis, MO,
USA) and phosphatase inhibitors (Roche Diagnostics, Mannheim,
Germany). To remove the insoluble materials, lysates were centrifuged
at 10 000g for 20 min at 4 °C. The protein concentrations in the
lysates were examined using a BCA protein assay kit (Pierce, Rockford,
IL, USA) according to the manufacturer protocol. The protein
concentration for each sample was adjusted to an equal amount with
different volumes of loading buffer and denatured in boiling water for
5 min. To separate different proteins, equal aliquots (40 μg) of protein
samples were subjected to 12% polyacrylamide gel electrophoresis and
then electrotransferred to PVDF membranes at 25 V and 1.5A for 60
min. The membranes were blocked with 5% nonfat milk in Tris-
buffered saline containing 0.1% Tween-20 (TBST) for 2 h. After being
washed with TBST three times, the membranes were incubated with
target protein-specific antibodies overnight at 4 °C, followed by
incubating with secondary antibodies with conjugated horseradish
peroxidase (HRP) at ambient temperature for 1.5 h. Peroxidase
activity was visualized using the chemiluminescence method with an
ECL kit (Bio-Rad, Hercules, CA, USA) with ChemiDoc XRS+(Bio-
Rad). β-Actin and α-tubulin were used as internal controls.
Fecal DNA Extraction and Amplification. Four mice from the 8
mice in each diet group were randomly selected for fecal microbiome
analyses. The QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA)
was used to isolate total bacterial DNA from the frozen fecal samples
according to the manufacturer’s instructions. The extracted DNA was
measured for concentrations using a Nano-Drop 1000 spectropho-
tometer (Nano-Drop Technologies, Wilmington, DE). The extracted
DNA samples were stored at −80 °C for further analysis. To examine
the composition of the microbiota community, universal forward
primers 338 F (5′-ACTCCTACGGGAGGCAGCA-3′) and the
reverse primer 806 R (5′-GGACTACHVG GGTWTCTAAT-3′)
targeting the V3−V4 region of the 16S rRNA gene were utilized for
the amplification and sequencing. The targeted 16S rRNA gene was
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PCR amplified in triplicate. PCR conditions were a denaturing step at
95 °C for 3 min and 27 cycles of denaturing at 95 °C for 30 s,
annealing at 55 °C for 30 s, and extension at 72 °C for 45 s, followed
by a final annealing extension step at 72 °C for 10 min. PCR products
Table 1. Food Intake, Body Weight, Organ Weights, and Biochemical Parametersa
LFD HFD HFD+L HFD+H
food intake (g/day) 3.44 ± 0.33a 3.65 ± 0.52a 3.54 ± 0.32a 3.63 ± 0.42a
energy intake (kcal/day) 13.24 ± 1.27a 17.26 ± 2.45b 16.74 ± 1.51b 17.16 ± 1.99b
final body weight (g) 28.08 ± 0.98a 35.42 ± 1.74b 31.58 ± 3.18ab 28.37 ± 2.30a
organ weights (g)
liver 0.85 ± 0.07a 1.20 ± 0.11c 1.01 ± 0.08b 0.93 ± 0.11ab
kidney 0.33 ± 0.04a 0.41 ± 0.04b 0.37 ± 0.04b 0.38 ± 0.02b
testes 0.19 ± 0.03a 0.18 ± 0.08a 0.18 ± 0.03a 0.20 ± 0.02a
lung 0.16 ± 0.02a 0.18 ± 0.02a 0.17 ± 0.02a 0.19 ± 0.07a
brain 0.30 ± 0.01a 0.38 ± 0.01b 0.38 ± 0.06b 0.39 ± 0.03b
spleen 0.06 ± 0.01a 0.07 ± 0.02a 0.07 ± 0.01a 0.06 ± 0.01a
pancreas 0.11 ± 0.01a 0.12 ± 0.02a 0.14 ± 0.06a 0.13 ± 0.04a
thymus 0.04 ± 0.03a 0.05 ± 0.00a 0.04 ± 0.02a 0.03 ± 0.02a
epididymat fat 0.38 ± 0.09a 1.43 ± 0.14b 1.11 ± 0.40b 0.60 ± 0.31a
subcutaneous fat 0.28 ± 0.05a 0.92 ± 0.14c 0.79 ± 0.25bc 0.50 ± 0.22ab
inguinal fat 0.08 ± 0.03a 0.56 ± 0.06c 0.41 ± 0.19bc 0.30 ± 0.20ab
plasma parameters
TC (mg/dL) 131.74 ± 15.45a 193.67 ± 22.81b 179.36 ± 36.52ab 125.97 ± 13.5a
TG (mg/dL) 264.13 ± 43.47a 266.79 ± 31.32a 257.29 ± 25.32a 259.25 ± 53.55a
fasting glucose (mmol/dL) 11.43 ± 1.55a 12.07 ± 1.66a 11.30 ± 1.68a 11.50 ± 2.73a
insulin (ng/mL) 0.50 ± 0.05a 0.82 ± 0.11b 0.67 ± 0.12ab 0.55 ± 0.10a
HOMA-IR 6.27 ± 1.02a 10.87 ± 1.25b 8.31 ± 1.45ab 6.96 ± 0.89a
aLFD represents mice fed a low-fat diet, HFD represents mice fed a high-fat diet, and HFD+L and HFD+H represent mice fed HFD plus 100 and
300 mg/kg gypenosides, respectively. Values are means ± SD (n = 8); different letters indicate a significant difference of data in a row at P < 0.05.
Figure 1. Effect of gypenosides on hematoxylin and eosin (H&E) staining of inguinal white adipocyte tissue (iWAT) (A) and oral glucose tolerance
test (OGTT) and intraperitoneal insulin tolerance test (IPITT) (B). LFD represents mice fed a low-fat diet, HFD represents mice fed a high-fat diet,
and HFD+L and HFD+H represent mice fed HFD plus 100 and 300 mg/kg gypenosides, respectively. Values are means ± SD (n = 8). Values
marked with different letters are significantly different from each other at P < 0.05.
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were visualized, purified using a Mini Elute PCR purification kit
(AXYGEN), and quantified using an ABI GeneAmp1 9700 system.
Sequencing was accomplished on the Illumina MiSeq platform at
Shanghai Majorbio Biopharm Technology Co., Ltd. (Shanghai,
China). The 16S rDNA sequences were deposited with the NCBI
short reads archive database with a study accession number of
PRJNA303100.
Bioinformatics Analysis and Statistical Analyses. The
processing and bioinformatics analysis of the sequencing data were
similar to that described in the previous study.21 Raw fastq files were
demultiplexed and quality-filtered using QIIME (version 1.9.1) under
the following conditions: (1) the 300 bp reads were truncated at any
site receiving an average quality score < 20 over a 50 bp sliding
window, while the truncated reads shorter than 50 bp were discarded;
(2) exact barcode matching, 2 nucleotide mismatch in primer
matching and the reads having ambiguous characters were discarded,
and only sequences overlapping for over 10 bp were assembled
according to their overlap sequences; (3) the reads were discarded if
they could not be assembled.21
A 97% similarity cutoff was applied to cluster operational taxonomic
units (OTUs) with Usearch (version 7.1, http://drive5.com/uparse/),
and identified chimeric sequences were removed with UCHIME. The
taxonomy of each 16SrRNA gene sequence was examined using RDP
Classifier (http://rdp.cme.msu.edu/) against the silva (SSU123) 16S
rRNA database, and a confidence threshold was set at 70%. The linear
discriminant analysis effect size (LEfSe) method (http://huttenhower.
sph.harvard.edu/lefse/) was utilized on OUT table to identify
biomarkers. LEfSe analysis was performed with the alpha value of
0.05 for the factorial Kruskal−Wallis test among classes and the
threshold of 4.0 on the logarithmic LDA score for discriminative
features.
Data were expressed as mean ± SD. The statistical significance of
the difference was analyzed using one-way ANOVA, followed by
Tukey’s multiple comparison test. All statistical analyses were
performed with SPSS 21.0 software. P < 0.05 was considered to be
statistically significant. The graph was created on GraphPad Prism
(Version 6.00, Graphpad Software Inc., San Diego, CA, USA).
■ RESULTS AND DISCUSSION
Gypenosides Reduced HFD-Induced Body Weight
and Insulin Resistance. Gypenosides dose-dependently
decreased final body weight and fat accumulation in a high-
fat diet (HFD)-induced obese mouse model (Table 1).
Histological analysis for inguinal white adipose tissue suggested
that HFD promoted adipocyte hypertrophy with a significant
increase of adipocyte area compared to the LFD group, and this
was prevented by gypenosides supplementation in a dose-
dependent manner (Figure 1A). The effects of gypenosides on
body weight and obesity parameters were not a result of a
reduced food consumption as there was no difference in the
Figure 2. Effect of gypenosides on genes expression in brown adipocyte tissue (BAT) at both protein (A) and mRNA (B) levels. LFD represents
mice fed a low-fat diet, HFD represents mice fed a high-fat diet, and HFD+L and HFD+H represent mice fed HFD plus 100 and 300 mg/kg
gypenosides, respectively. Values are means ± SD (n = 8): (*) significant difference between HFD and LFD groups (P < 0.05), (#) significant
difference between the gypenosides treatment group and the HFD group (P < 0.05).
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food intakes among the treatment groups (Table 1). A 300 mg/
kg/day gypenosides treatment with HFD also significantly
reduced epididymal, subcutaneous, and inguinal fats by 58%,
45.7%, and 46.4%, respectively, compared with the HFD group
(P < 0.05), suggesting their potential in inhibiting fat
accumulation (Table 1). Moreover, no significant differences
were observed on the fasting blood glucose (Table 1) and in
the oral glucose tolerance test (OGTT) among the treatment
groups (Figure 1B). The AUCglucose for the OGTT reflects the
degree of glucose tolerance in the mice, and no significant
difference among treatment groups (Figure 1B) indicated no
glucose intolerance under the experimental conditions.
Interestingly, treatment with 300 mg/kg gypenosides signifi-
cantly reduced the plasma insulin concentration and the
Figure 3. Effect of gypenosides on immunohistochemistry of UCP-1 (A), and genes expression in inguinal white adipocyte tissue (iWAT) at both
mRNA (B) and protein (C) levels. LFD represents mice fed a low-fat diet, HFD represents mice fed a high-fat diet, and HFD+L (HFD+TJS-L) and
HFD+H (HFD+TJS-H) represent mice fed HFD plus 100 and 300 mg/kg gypenosides, respectively. Values are means ± SD (n = 8): (*) significant
difference between HFD and LFD groups (P < 0.05); (#) significant difference between the gypenosides treatment group(s) and the HFD group (P
< 0.05).
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HOMA-IR by 14.9% and 36%, respectively, compared with that
of the high-fat diet group (P < 0.05), indicating a possible
reduction in obese-associated insulin resistance (Table 1). The
improvement of insulin resistance was also supported by the
intraperitoneal insulin tolerance test (IPITT) result (Figure
1B). After intraperitoneal injection of insulin, the plasma
glucose levels of mice in the HFD group decreased significantly
less than the other three diet groups at 30 min, but the four
groups had no difference in their plasma glucose levels at 60,
90, and 120 min (Figure 1B), indicating the potential of
gypenosides in improving insulin sensitivity in the HFD mice.
The AUCglucose data for IPITT also showed that HFD induced
insulin intolerance in mice, and gypenosides treatment was able
to reverse the insulin intolerance in a dose-dependent matter.
These results implied that gypenosides could reduce body
weight, fat accumulation, and overweight-induced insulin
resistance.
Gypenosides-Induced Thermogenesis of BAT and
Inguinal WAT (iWAT). The effect of gypenosides on the
selected BAT thermogenic progress marker proteins including
PPAR-γ coactivator-1α (PGC-1α), PR domain containing 16
(PRDM16), and UCP1 were investigated using a western-blot
analysis, and two representative SDS-PAGE results from eight
animals in each dietary treatment group are reported in Figure
2A. Compared with the HFD mice, supplementation with
gypenosides significantly increased UCP-1, PGC-1α, and
PRDM16 protein expressions in a dose-dependent manner (P
< 0.05, Figure 2A). UCP1 is important for BATs in
transforming stored chemical energy into heat, a thermal
energy, and protecting mice from overweight and cold,4
whereas increased PGC-1α and PRDM16 are associated with
adipocyte tissue energy expenditure. Moreover, gypenosides
were able to significantly promote the mRNA expressions of
mitochondrial activity and lipid β-oxidation genes, including
PGC-1α, PRDM16, cell death-inducing DNA fragmentation
factor (Cideα), cytochrome c oxidase, subunit VII α (Cox7α),
long-chain fatty acids-like 3 (Elovl3), carnitine palmitoyl
transterase-1 (CPT1), and medium-chain acyl-CoA dehydro-
Figure 4. Fecal bacterial community at the phylum level (A). Relative abundance of different bacterial phylum within the different communities (B−
D). LFD represents mice fed a low-fat diet, HFD represents mice fed a high-fat diet, and HFD+L and HFD+H represent mice fed HFD plus 100 and
300 mg/kg gypenosides, respectively. Values are means ± SD (n = 4). Values marked with different letters are significantly different from each other
at P < 0.05.
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genase (MCAD) (P < 0.05, Figure 2B) in a dose-dependent
manner in the HFD-induced obese mouse model.
It has been reported that beige adipocytes from WATs are
also UCP1 positive and may be induced to express thermogenic
genes and stimulate respiration and energy expenditure besides
the classical brown adipocytes from BATs, and the progress has
been described as browning.22 Gypenosides was further
evaluated for their potential on thermogenic program in
WATs. Inguinal adipose tissue (iWAT) was used for UCP1
immunohistochemistry, and the results indicated that gypeno-
sides treatment resulted in much denser small white adipocytes
with clusters of UCP1 expressing in the multilocular adipocytes
(Figure 3A). Meanwhile, gene expressions of the important
markers of mitochondrial activity and brown adipocyte
function, including PGC-1α, PRDM16, UCP-1, Cideα,
Cox7α, and Elovl3, were significantly increased by gypenosides
treatment compared with the HFD control group (P < 0.05,
Figure 3B). Increased expression of key brown adipocyte
Figure 5. LEfSe analysis of key genera of mice gut microbiota. Histogram shows the LDA scores computed for features (OTU level) differentially
abundant between different treatments. The higher the score is, the more important the role is (A). Cladogram shows that brown dots are
unimportant bacteria in any groups; other colored dots are important bacteria in the group labeled with the same color (B). LFD represents mice fed
a low-fat diet, HFD represents mice fed a high-fat diet, and HFD+L and HFD+H represent mice fed HFD plus 100 and 300 mg/kg gypenosides,
respectively.
Journal of Agricultural and Food Chemistry Article
DOI: 10.1021/acs.jafc.7b03382
J. Agric. Food Chem. XXXX, XXX, XXX−XXX
G
marker proteins including PGC-1α, PRDM16, and UCP1 was
also confirmed by a Western blot analysis (Figure 3C). These
data indicated that gypenosides could increase the BAT
thermogenic progress and induce adipocyte browning in iWAT.
Recently, increasing energy expenditure through nonshiver-
ing thermogenesis is considered a possible treatment of
metabolic syndromes.3,23 Promoting energy expenditure
through BAT thermogenesis or browning of iWAT is of
significant interest as a potential antiobesity approach due to
BAT and beige fat’s ability to metabolize vast amounts of
glucose and lipids in proportion to their tissue mass.23,24 In this
study, dietary gypenosides showed potential in preventing high-
fat diet-induced overweight and insulin resistance through
thermogenesis by activating PGC-1α and PRDM16 genes
expression. It has been shown that ectopic expression of PGC-
1α, a master regulator of mitochondrial biogenesis and
function, in white adipocytes induced acquisition of BAT
features, such as thermogenic markers expression.25 For
example, dietary luteolin induced thermogenesis and browning
in differentiated primary adipocytes through upregulating
AMPK/PGC1α pathway. It was also reported that PRDM16
was critical in the development and function of brown and
beige adipocytes, and both beige adipocytes and PRDM16 were
required for the “browning” of white fat tissues.26 The
observations in this study were consistent with previous studies
that PGC1α and PRDM16 could be the key genes for
thermogenesis effect of gypenosides. Besides, Broeders et al.
showed that chenodeoxycholic acid (CDCA), a bile acid,
promoted mitochondrial uncoupling via TGR5 in brown
adipocytes and increased brown fat activity and energy
expenditure in women.27 Bile acids were thought to increase
BAT activity and enhance energy expenditure in murine BAT
and human skeletal muscles through activating the TGR5 G
protein-coupled receptor.27,28 Considering our previous study
that gypenosides could increase bile acids excretion,19 it is
interesting to further investigate whether TGR5 may be
another possible gene involved in the brown adipocyte function
and white adipocyte browning effects of gypenosides.
Gypenosides Reversed HFD-Induced Gut Dysbiosis.
The gut microbiota is highly associated with development of
obesity and type II diabetes. Feeding a HFD resulted in
microbiota dysbiosis and increased fasting glucose levels and
insulin intolerance.29 The effect of gypenosides on gut
microbiota composition in mice was examined by performing
a sequencing-based analysis of bacterial 16S rRNA (V3−V4
region) in cecal faeces. A data set of 896 327 high-quality 16S
rDNA gene sequences was obtained from 16 samples through
MiSeq sequencing analysis, and the range in the number of
reads for 16 samples was 31896−63986, while the average
number of sequence reads was 47 826 for each sample. The
sequences were clustered with representative ones with a
sequence identity cutoff of 97%. At the phylum level, 11 phyla
were identified in the faeces (Figure 4A). Firmicutes and
Bacteroidetes are the two most abundant bacterial phyla under
the experimental conditions, and the switch from a low-fat diet
to a high-fat diet changed the composition of the mouse gut
microbiota (Figure 4B−D). In addition, 300 mg/kg/day
gypenosides treatment significantly increased Verrucomicrobia
content, which played a role in prebiotics (Figure 4A). The gut
microbiota of the HFD group mice was characterized by a
significant 3.2-fold increase of the Firmicutes to Bacteroidetes
ratio compared with that of the low-fat diet group, and the ratio
was decreased by 20% and 58.6% by the gypenoside treatment
at a dose of 100 and 300 mg/kg/day, respectively (P < 0.05,
Figure 4D). Firmicutes are Gram-positive bacteria, which are
involved in energy resorption and obesity. Bacteroidetes have
been shown to exert immunomodulatory properties on the
host. The change in the ratio of Firmicutes to Bacteroidetes may
alter the weight gain or loss of the hosts. A high ratio of
Frimcutes to Bacteroidetes has been found in obese mice and
human adults compared to lean mice and human adults,
respectively.17 Gypenosides treatment significantly decreased
the ratio of Firmicutes to Bacteroidetes, which might be another
possible mechanism involved in the effect of gypenoside in
reducing the development of obesity and insulin resistance in
HFD mice.
In addition, to identify the characteristic bacteria which were
specific for each treatment group, LEfSe analysis based on the
nonparametric factorial Kruskal−Wallis (KW) sum-rank test
was applied. According to a pairwise comparison between the
gut microbiota among the different treatment groups, high-dose
gypenosides treatment significantly increased the abundance of
genus Akkermansia and Lactobacillus and phylum Verrucomicro-
bia compared with the LFD and HFD control groups (P < 0.05,
Figure 5). Gypenosides significantly stimulated Akkermansia at
a dose of 300 mg/kg/day. Akkermansia muciniphila (A.
muciniphila), belonging to Verrucomicrobia, made a large
contribution to the observed differences in the gut microbial
compositions in the LFD, HFD, and HFD plus high dose of
gypenosides mice (P < 0.05). A. muciniphila is a mucin-
degrading bacterium commonly found in human gut. A.
muciniphila has been inversely associated with the risk of
obesity, diabetes, inflammation, and metabolic disorders.15 A.
muciniphila may produce a number of fermentation products,
including short-chain fatty acids (SCFA), which are substrates
for gluconeogenesis and are involved in signaling to the host by
activating G-protein-coupled receptors such as GPR41/43 and
TGR-5. They could trigger the release of the hormone
glucagon-like peptide-1(GLP-1), leading to an improved
glucose homeostasis. Due to its beneficial activities against
obesity and diabetes, A. muciniphila has drawn much attention
for research and development in recent years.15,30,31 A number
of human and animal studies have shown that the abundance of
A. muciniphila in the gut can be enhanced through dietary
interventions,32 which has been considered a significant
beneficial effect. The results from this study suggested that
gypenosides might be a preferable prebiotics nutrient for A.
muciniphila. Taken together, the data from this study suggested
that altering gut microbiota might play an important role in an
overall beneficial effect of gypenosides in reducing the
development of obesity and the related insulin resistance.
This study showed that gypenoside could improve glycolipid
metabolism and stimulate BAT activity, WAT browning, and
lipid β-oxidation while decreasing the ratio of Firmicutes to
Bacteroidetes and enhancing the abundance of Akkermansia
muciniphila. These results suggested that gypenosides intake
might serve as a possible approach to reduce the risk of the
diet-induced overweight and insulin intolerance. In addition,
gypenosides might prevent the HFD-induced obesity and
insulin resistance through simultaneously promoting energy
expenditure and modulating gut microbiota.
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